Elite Journal of Medical Sciences. Volume 2 Issue 6(2024), 10-23
https://epjournals.com/journals/EJMS

# HIV-Specific T-Cell Responses in Infants: A Review

**Emmanuel Ifeanyi Obeagu**

**Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com**

## Abstract

Infants infected with HIV face unique immunological challenges due to the immaturity of their immune systems, which impacts the development and functionality of T-cell responses against the virus. This review synthesizes current knowledge on the characteristics, development, and clinical implications of HIV-specific T-cell responses in infants, highlighting key factors influencing immune priming, viral control, and immune exhaustion in early life. The development of adaptive immunity in infants is characterized by gradual maturation of T lymphocytes and immune responses, influenced by factors such as age, timing of infection, and maternal HIV status. HIV-specific T-cell responses in infants differ from those in adults, often exhibiting delayed and suboptimal activation, which contributes to viral persistence and disease progression. Clinical implications of HIV-specific T-cell responses in infants extend to disease progression, treatment outcomes, and immune reconstitution strategies. Early ART initiation in infants suppresses viral replication, preserves immune function, and improves T-cell responses, but challenges such as immune exhaustion and regulatory T-cell expansion underscore the need for personalized treatment approaches. Therapeutic vaccination strategies targeting conserved HIV epitopes and promoting T-cell memory formation offer promising avenues for enhancing immune surveillance and achieving sustained viral remission in pediatric populations.

***Keywords:*** *HIV, T-cell responses, infants, immune development, adaptive immunity*

## Introduction

Human Immunodeficiency Virus (HIV) infection remains a significant global health challenge, particularly affecting vulnerable populations such as infants and young children. Pediatric HIV infection differs substantially from adult infection due to unique immunological, developmental, and clinical characteristics that influence disease progression and treatment outcomes.[1-2] Pediatric HIV infection continues to pose a substantial public health burden worldwide, particularly in sub-Saharan Africa and other resource-limited settings where access to healthcare services and prevention programs may be limited. Despite global efforts to reduce mother-to-child transmission through interventions such as antiretroviral therapy (ART) and prevention of mother-to-child transmission (PMTCT) programs, many infants still acquire HIV vertically, highlighting ongoing challenges in prevention and early diagnosis.[3-4] Infants are born with an immature immune system

that undergoes rapid development during the first years of life. The adaptive immune system, including T lymphocytes, undergoes maturation characterized by changes in T-cell receptor diversity, antigen responsiveness, and cytokine production profiles. This developmental trajectory influences the quality and magnitude of T-cell responses to pathogens, including HIV.[5-6] HIV-specific T-cell responses in infants differ from those in adults in several key aspects. Infants may mount weaker and narrower T-cell responses against HIV antigens due to factors such as limited exposure to diverse antigens, reduced thymic output of naïve T cells, and regulatory T-cell dominance. Studies have shown that infants infected perinatally with HIV often exhibit delayed and suboptimal activation of T-cell responses, which contributes to viral persistence and disease progression. Moreover, immune exhaustion and viral escape mechanisms further complicate effective immune control in pediatric HIV infection.[7-8]

Early diagnosis of HIV infection in infants is critical for optimizing treatment outcomes and preventing disease progression. Prompt initiation of ART suppresses viral replication, preserves immune function, and improves HIV-specific T-cell responses by reducing viral antigen exposure and immune activation. Early intervention strategies, including newborn screening and point-of-care diagnostics, are essential for identifying HIV-infected infants early in life and initiating timely treatment to prevent irreversible immune damage and improve long-term prognosis.[9-11] Maternal factors play a significant role in shaping HIV-specific T-cell responses in infants. Maternal HIV status, viral load, and timing of ART initiation during pregnancy influence maternal-fetal immune interactions, placental transfer of antibodies, and infant susceptibility to HIV infection. Maternal ART regimens impact viral reservoirs and the risk of vertical transmission, highlighting the importance of maternal health in mitigating infant HIV acquisition and optimizing immune responses in exposed infants.[12-15] Pediatric HIV care faces unique challenges, including barriers to healthcare access, adherence to ART regimens, management of co-infections, and long-term monitoring of immune reconstitution. Infants may experience treatment-related complications, drug resistance, and immune reconstitution inflammatory syndrome (IRIS), necessitating multidisciplinary approaches to comprehensive pediatric HIV care. Addressing these challenges requires innovative strategies tailored to the developmental and immunological needs of infants infected with HIV.[16-19]

**Impact of HIV-Specific T-Cell Responses on Clinical Outcomes**

HIV-specific T-cell responses significantly influence clinical outcomes in pediatric HIV infection, including viral control, disease progression, and immune reconstitution. Effective T-cell responses are associated with reduced viral replication, improved CD4+ T cell counts, and lower risk of opportunistic infections. Conversely, dysfunctional T-cell responses, characterized by immune exhaustion or inadequate antigen recognition, contribute to persistent viral reservoirs, chronic immune activation, and increased susceptibility to AIDS-related complications.[20-22] Current therapeutic interventions aim to enhance HIV-specific T-cell responses in infants through early ART initiation, immune modulators, and therapeutic vaccination strategies. Early ART improves viral suppression and immune function, but challenges such as immune exhaustion and regulatory T-cell expansion highlight the need for adjunctive therapies targeting immune dysregulation. Therapeutic vaccines targeting conserved HIV epitopes and promoting T-cell memory formation

offer potential for enhancing immune surveillance and achieving sustained viral remission in pediatric populations.[23-27] During early life, infants undergo a profound developmental journey of their immune system, particularly in the context of adaptive immunity, which plays a crucial role in recognizing and responding to pathogens like HIV.[28] The ontogeny of adaptive immunity in infants is characterized by sequential developmental milestones that shape the functionality and responsiveness of immune cells. At birth, infants have a relatively naïve immune system with limited exposure to antigens. The thymus, a primary organ for T cell maturation, plays a pivotal role early in life by producing naïve T cells that recognize specific antigens. However, the output of naïve T cells from the thymus decreases with age, affecting the diversity and repertoire of T cell receptors (TCRs) available for antigen recognition.[29-32]

**Maturation of T Cells**

T lymphocytes, crucial players in adaptive immunity, undergo maturation and differentiation processes in infancy. Initially, the neonatal immune system is biased towards T helper 2 (Th2) responses, which are involved in antibody production and immune regulation. This bias gradually shifts towards T helper 1 (Th1) responses, which are critical for cellular immunity and the activation of cytotoxic T cells. The maturation of T cells involves changes in cytokine production profiles and the acquisition of memory T cells, which play a vital role in immune memory and long-term protection against pathogens like HIV.[33-35] The process of adaptive immune development in infants is profoundly influenced by antigen exposure, including microbial encounters through breastfeeding, environmental pathogens, and vaccines. Early life exposures shape immune responses by promoting the differentiation of memory T cells and enhancing immune recognition of specific antigens. However, HIV infection in infants disrupts this developmental process, potentially leading to immune dysregulation, impaired T cell function, and ineffective immune responses against the virus.[36-40] HIV infection in infants poses unique challenges to the development of adaptive immunity. The virus directly targets CD4+ T cells, which are crucial for orchestrating immune responses, and impairs the thymic function, reducing the production of naïve T cells. This leads to a skewed T cell repertoire and compromised T cell responses against HIV antigens. Furthermore, HIV-induced chronic immune activation and inflammation contribute to T cell exhaustion, immune senescence, and an increased susceptibility to opportunistic infections. These factors collectively impair the development and maintenance of effective adaptive immune responses in HIV-infected infants.[41-45]

**Role of Maternal Antibodies and Breastfeeding**

Maternal antibodies transferred across the placenta and through breast milk provide passive immunity to infants during the early months of life. Maternal HIV-specific antibodies can confer partial protection against HIV transmission, but they wane over time, leaving infants vulnerable to infection. Breastfeeding, while beneficial for overall immune development, poses a risk of HIV transmission in infants born to HIV-positive mothers. Balancing the benefits of breastfeeding with the risk of HIV transmission requires careful consideration in the context of maternal ART adherence and viral suppression.[46-50] Initiating antiretroviral therapy (ART) early in HIV-infected infants is critical for suppressing viral replication and preserving immune function. However,

achieving immune reconstitution poses challenges due to the residual effects of HIV on thymic function, T cell exhaustion, and the persistence of viral reservoirs. ART promotes the recovery of CD4+ T cell counts and reduces the viral load, but long-term immune recovery may be incomplete, necessitating lifelong therapy and continuous monitoring of immune function.[51-53]

**Characteristics of HIV-Specific T-Cell Responses**

HIV-specific T-cell responses are critical components of the immune defense against Human Immunodeficiency Virus (HIV) infection. These responses are characterized by their specificity to viral antigens and their role in controlling viral replication and disease progression.[54] HIV-specific T-cell responses are directed against viral antigens presented on infected cells. CD4+ T cells recognize peptides derived from HIV proteins presented on major histocompatibility complex (MHC) class II molecules, while CD8+ T cells recognize peptides presented on MHC class I molecules. These antigens include proteins such as Gag, Pol, and Env, which are essential for viral replication and assembly. The specificity of HIV-specific T cells enables targeted immune responses against infected cells, aiming to eliminate viral reservoirs and control viral replication.[55-57] The T-cell receptor (TCR) diversity and clonality play crucial roles in HIV-specific T-cell responses. TCR diversity allows recognition of a wide range of HIV epitopes, contributing to effective immune surveillance and response. During HIV infection, clonal expansion of T cells specific to dominant epitopes occurs, reflecting the adaptive immune response's attempt to control viral replication. However, HIV-specific T-cell responses can be limited by TCR repertoire skewing, wherein the immune system focuses on a subset of viral epitopes, potentially allowing viral escape from immune surveillance.[58-61]

**Functional Properties: Cytokine Production and Cytotoxic Activity**

HIV-specific T cells exhibit functional properties that contribute to viral control and immune regulation. CD4+ T cells produce cytokines such as interleukin-2 (IL-2), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α), which orchestrate immune responses and support CD8+ T cell cytotoxic activity. CD8+ T cells, in turn, exert cytotoxic functions by releasing perforin and granzyme B, leading to apoptosis of infected cells. The balance between cytokine production and cytotoxic activity is critical for maintaining effective immune surveillance and minimizing immune activation and tissue damage.[62-66] Memory T-cell responses are essential components of HIV-specific immunity, providing long-term protection against viral reactivation. Central memory T cells (TCM) and effector memory T cells (TEM) retain antigen-specific memory and respond rapidly upon re-exposure to HIV antigens. Memory T cells undergo phenotypic and functional changes during chronic HIV infection, characterized by upregulation of inhibitory receptors (e.g., PD-1, Tim-3) and decreased proliferative capacity, contributing to immune exhaustion and impaired viral control.[67-70]

Chronic HIV infection induces immune exhaustion and dysfunction within HIV-specific T-cell populations, characterized by progressive loss of effector functions and sustained expression of inhibitory receptors. Exhausted T cells exhibit reduced cytokine production, impaired proliferation, and compromised cytotoxic activity, contributing to viral persistence and disease

progression. Strategies aimed at reversing immune exhaustion, such as immune checkpoint blockade and therapeutic vaccination, are being investigated to restore T-cell function and enhance immune control in HIV-infected individuals.[71-74] HIV-specific T-cell responses exhibit heterogeneity and plasticity in their phenotypic and functional profiles across different stages of infection and among individuals. Factors influencing this heterogeneity include viral diversity, host genetics, ART regimen, and immune activation status. Heterogeneous T-cell responses contribute to variable outcomes in disease progression and treatment response among HIV-infected individuals, highlighting the importance of personalized medicine approaches in HIV care.[75-77] Viral escape mutations in HIV proteins, particularly in regions targeted by T-cell responses, pose challenges to effective immune control. These mutations allow the virus to evade recognition and destruction by HIV-specific T cells, leading to the establishment of viral reservoirs and ongoing viral replication. The dynamic interplay between viral evolution and T-cell responses shapes the trajectory of HIV infection and influences the efficacy of therapeutic interventions aimed at enhancing immune surveillance.[78-80]

**Clinical Implications and Challenges**

These responses play a pivotal role in viral control, disease progression, immune reconstitution, and the efficacy of therapeutic interventions. However, they also present challenges that impact clinical management and therapeutic outcomes.[81] Effective HIV-specific T-cell responses are essential for controlling viral replication and preventing disease progression. CD8+ T cells play a central role in eliminating virus-infected cells through cytotoxic activity, while CD4+ T cells support immune regulation and orchestrate broader immune responses. Robust T-cell responses, characterized by polyfunctionality and diversity, correlate with lower viral loads and slower disease progression. Conversely, dysfunctional or exhausted T-cell responses contribute to persistent viral replication, immune activation, and increased susceptibility to opportunistic infections, leading to accelerated disease progression.[82-86] Initiation of antiretroviral therapy (ART) is crucial for restoring immune function and suppressing viral replication in HIV-infected individuals. Effective ART promotes the recovery of CD4+ T cells and enhances HIV-specific T-cell responses by reducing viral antigen exposure and immune activation. However, immune reconstitution can be incomplete, particularly in individuals with advanced disease or prolonged viral exposure before treatment initiation. Immune reconstitution may be hampered by residual immune dysfunction, impaired thymic output, and persistent HIV reservoirs, necessitating long-term monitoring and management to prevent treatment failure and disease relapse.[87-90]

**Challenges in Therapeutic Interventions**

Challenges in therapeutic interventions aimed at enhancing HIV-specific T-cell responses include immune exhaustion, viral escape mutations, and variability in treatment response among individuals. Immune exhaustion, characterized by upregulation of inhibitory receptors (e.g., PD-1, Tim-3) and functional impairment, limits the efficacy of T-cell responses and compromises immune surveillance. Strategies to reverse immune exhaustion, such as immune checkpoint blockade and therapeutic vaccination, are under investigation but face challenges related to treatment durability, immune activation, and potential adverse effects.[91-92] Chronic immune

activation and inflammation are hallmark features of HIV infection and contribute to T-cell dysfunction, immune exhaustion, and non-AIDS-related comorbidities. Persistent activation of innate and adaptive immune responses leads to accelerated immune aging, cardiovascular disease, neurocognitive impairment, and other inflammatory conditions in HIV-infected individuals. Managing immune activation requires comprehensive approaches that combine ART with adjunctive therapies targeting immune dysregulation, inflammation pathways, and co-infections to improve overall health outcomes and quality of life.[93-95] Advances in understanding the variability of HIV-specific T-cell responses among individuals underscore the importance of personalized medicine approaches in HIV care. Tailoring treatment strategies based on host genetics, viral characteristics, immune status, and treatment history can optimize therapeutic outcomes and minimize treatment-related complications. Precision medicine approaches aim to identify biomarkers of immune activation, predict treatment responses, and guide individualized therapeutic interventions, including immunotherapy and therapeutic vaccination strategies.[96-98] Long-term monitoring of HIV-specific T-cell responses is essential for assessing treatment efficacy, detecting immune dysfunction, and predicting clinical outcomes in HIV-infected individuals. Routine immunological assessments, including CD4+ and CD8+ T-cell counts, T-cell function assays, and viral load measurements, inform clinical decision-making and guide adjustments in ART regimens. Monitoring immune reconstitution inflammatory syndrome (IRIS), opportunistic infections, and non-AIDS-related complications ensures comprehensive management of HIV infection and improves long-term prognosis.[99-100]

**Therapeutic Strategies and Vaccination**

Therapeutic strategies and vaccination play crucial roles in managing HIV infection, focusing on enhancing immune responses, controlling viral replication, and achieving sustained remission. These approaches encompass a range of interventions aimed at augmenting HIV-specific T-cell responses and improving clinical outcomes in HIV-infected individuals.[100] Antiretroviral therapy (ART) remains the cornerstone of HIV treatment, effectively suppressing viral replication and preserving immune function. Early initiation of ART in HIV-infected individuals, including infants and children, improves immune reconstitution and reduces the risk of disease progression. ART regimens typically combine drugs targeting different stages of the viral life cycle, such as reverse transcriptase inhibitors, protease inhibitors, and integrase inhibitors. Continuous adherence to ART is essential to achieve and maintain viral suppression, prevent drug resistance, and mitigate long-term complications associated with HIV infection.[101] Immune modulatory therapies aim to enhance HIV-specific T-cell responses by targeting immune dysregulation and promoting immune surveillance. Approaches include: IL-2 administration stimulates T-cell proliferation and enhances immune function, potentially improving immune reconstitution in HIV-infected individuals. Immune checkpoint inhibitors, such as antibodies targeting PD-1, CTLA-4, and Tim-3, aim to reverse T-cell exhaustion and restore immune responses against HIV. Clinical trials are evaluating their efficacy and safety in HIV cure strategies. Cytokines like interleukin-7 (IL-7) and interleukin-15 (IL-15) are being investigated to boost T-cell function and promote immune reconstitution in individuals with HIV.[102]

**Therapeutic Vaccination**

Vaccines containing HIV-specific peptides or proteins aim to stimulate T-cell responses against conserved epitopes of the virus. These vaccines are designed to boost existing immune responses or prime the immune system for enhanced antiviral activity. Dendritic cells loaded with HIV antigens are used to stimulate HIV-specific T-cell responses. This approach leverages the antigen-presenting capabilities of dendritic cells to enhance immune recognition and response against HIV. bNAbs target highly conserved regions of the HIV envelope glycoprotein, neutralizing diverse strains of the virus. They are being explored not only for their potential as therapeutic agents to control viral replication but also as components of therapeutic vaccine strategies to prevent viral escape. CRISPR/Cas9 technology and other gene editing tools are investigated to disrupt HIV co-receptor genes (e.g., CCR5) in T cells or hematopoietic stem cells, rendering them resistant to HIV infection. Introduction of genes encoding HIV-specific T-cell receptors (TCRs) or chimeric antigen receptors (CARs) into T cells enhances their ability to recognize and target HIV-infected cells. Engineered T cells can potentially provide long-term immune surveillance and control of viral replication.[103]

## Conclusion

The field of therapeutic strategies and vaccination for HIV infection has made significant strides, yet challenges persist in achieving sustained viral remission and functional cure. HIV-specific T-cell responses play a central role in controlling viral replication, maintaining immune function, and influencing clinical outcomes in infected individuals. Antiretroviral therapy (ART) remains the cornerstone of HIV treatment, effectively suppressing viral replication and preserving immune function. Early initiation of ART in infants and adults improves immune reconstitution and reduces the risk of disease progression. However, achieving durable viral suppression and immune reconstitution poses challenges, including the persistence of viral reservoirs, immune exhaustion, and the emergence of drug-resistant strains. Immune modulatory therapies, such as interleukin therapies and immune checkpoint inhibitors, aim to enhance HIV-specific T-cell responses by reversing immune exhaustion and restoring immune function. These therapies hold promise in augmenting immune surveillance and controlling viral replication but require further research to optimize efficacy, safety, and long-term outcomes. Therapeutic vaccination strategies aim to induce or enhance HIV-specific immune responses, potentially achieving viral control or functional cure. Vaccines targeting conserved HIV epitopes and dendritic cell-based vaccines are under investigation to stimulate robust T-cell responses and prevent viral escape. Gene therapy approaches, including gene editing and gene transfer technologies, offer innovative avenues to engineer HIV-resistant immune cells and enhance T-cell-mediated immunity.

## References

1. Yu JC, Khodadadi H, Malik A, Davidson B, Salles ÉD, Bhatia J, Hale VL, Baban B. Innate immunity of neonates and infants. Frontiers in immunology. 2018; 9:1759.
2. Goenka A, Kollmann TR. Development of immunity in early life. Journal of Infection. 2015;71: S112-120.
3. Lewis DB, Weitkamp JH, Levy O. Developmental immunology and role of host defenses in fetal and neonatal susceptibility to infection. In Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant 2025: 73-159. Elsevier.

**Citation**: Obeagu EI. HIV-Specific T-Cell Responses in Infants: A Review. Elite Journal of Medical Sciences, 2024; 2(6):10-23

4. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV, 2024; 2(1): 16-30
5. Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review, 2024; 2(1): 37-50
6. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.
7. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).
8. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review, 2024; 2(1): 17-41
9. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
10. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 2(1): 51-64
11. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. Elite Journal of Medicine, 2024; 2(1): 1-16
12. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 14-32
13. Kuhn L, Meddows-Taylor S, Gray G, Tiemessen C. Human immunodeficiency virus (HIV)–specific cellular immune responses in newborns exposed to HIV in utero. Clinical infectious diseases. 2002;34(2):267-276.
14. Muenchhoff M, Prendergast AJ, Goulder PJ. Immunity to HIV in early life. Frontiers in immunology. 2014; 5:391.
15. Geng ST, Zhang ZY, Wang YX, Lu D, Yu J, Zhang JB, Kuang YQ, Wang KH. Regulation of gut microbiota on immune reconstitution in patients with acquired immunodeficiency syndrome. Frontiers in microbiology. 2020; 11:594820.
16. Obeagu EI, Obeagu, GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 24-36
17. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51.
18. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV, 2024; 2(3): 14-26
19. Obeagu EI, Elamin EAI Obeagu GU. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2(3): 111-117
20. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73

21. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58
22. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science, 2024; 2(3): 23-35
23. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology, 2024; 2(2): 43-59
24. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2(3): 42-57
25. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science, 2024; 2(2): 5-15
26. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science, 2024; 2(3): 59-72
27. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
28. Yu JC, Khodadadi H, Malik A, Davidson B, Salles ÉD, Bhatia J, Hale VL, Baban B. Innate immunity of neonates and infants. Frontiers in immunology. 2018; 9:1759.
29. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nature Reviews Immunology. 2007;7(5):379-390.
30. Pieren DK, Boer MC, de Wit J. The adaptive immune system in early life: The shift makes it count. Frontiers in immunology. 2022; 13:1031924.
31. Rackaityte E, Halkias J. Mechanisms of fetal T cell tolerance and immune regulation. Frontiers in immunology. 2020; 11:588.
32. Sereme Y, Toumi E, Saifi E, Faury H, Skurnik D. Maternal immune factors involved in the prevention or facilitation of neonatal bacterial infections. Cellular Immunology. 2024; 395:104796.
33. Zhang X, Zhivaki D, Lo-Man R. Unique aspects of the perinatal immune system. Nature Reviews Immunology. 2017;17(8):495-507.
34. Sanidad KZ, Zeng MY. Neonatal gut microbiome and immunity. Current opinion in microbiology. 2020; 56:30-37.
35. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
36. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.

links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf

37. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
38. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
39. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
40. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
41. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
42. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
43. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
44. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
45. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
46. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT:

assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.

47. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
48. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
49. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
50. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
51. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
52. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
53. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
54. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
55. Wilson EM, Sereti I. Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunological reviews. 2013;254(1):343-354.

56. Misgena DK. The pattern of immunologic and virologic responses to Highly Active Antiretroviral Treatment (HAART): Does success bring further challenges? Ethiopian Journal of Health Development. 2011;25(1):61-70.
57. Davenport MP, Khoury DS, Cromer D, Lewin SR, Kelleher AD, Kent SJ. Functional cure of HIV: the scale of the challenge. Nature Reviews Immunology. 2019;19(1):45-54.
58. Geretti AM, Brook G, Cameron C, Chadwick D, French N, Heyderman R, Ho A, Hunter M, Ladhani S, Lawton M, MacMahon E. British HIV Association guidelines on the use of vaccines in HIV-positive adults 2015. HIV medicine. 2016;17(53):S2-81.
59. Laupèze B, Del Giudice G, Doherty MT, Van der Most R. Vaccination as a preventative measure contributing to immune fitness. npj Vaccines. 2021;6(1):93.
60. Obeagu EI, Obeagu GU. Immunological Aspects of HIV Control in Perinatally Infected Infants: A Review**.** Elite Journal of Immunology, 2024; 2(6): 1-14
61. Obeagu EI, Obeagu GU. An update on Early Immunological Markers in HIV-Exposed Infants**.** Elite Journal of Immunology, 2024; 2(6): 15-25
62. Obeagu EI. Markers of Immune Activation in HIV-Exposed Infants. Elite Journal of Health Science, 2024; 2(6): 1-14
63. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
64. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
65. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
66. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
67. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
68. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
69. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
70. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.

71. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
72. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
73. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
74. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
75. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health. 2024;2(1):8-22.
76. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology. 2024;2(1):14-33.
77. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024;103(9): e37354.
78. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. Elite Journal of Immunology. 2024;2(1):1-3.
79. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology. 2024;2(1):34-46.
80. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
81. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine. 2024;2(1):35-46.
82. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com.;12(01).
83. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
84. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
85. Obeagu EI, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. Elite Journal of HIV. 2024;2(1):31-50.
86. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV. 2024;2(1):1-5.
87. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.

88. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Sciences. 2024;4(1):32-37.
89. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Sciences. 2024;4(1):38-44.
90. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science. 2024;2(1):33-42.
91. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
92. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine. 2024;2(2):104-115.
93. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology. 2024;2(1):47-64.
94. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.
95. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
96. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. Elite Journal of Public Health. 2024;2(1):22-34.
97. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.
98. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
99. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science. 2024;2(3):38-58.
100. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV. 2024;2(3):14-26.
101. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health. 2024;2(1):52-63.
102. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
103. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review. 2024;2(1):37-50.